Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUM 302

Next Previous
X
Search
Drug Profile

AUM 302

Alternative Names: AUM-302; IBL 302

Latest Information Update: 09 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spanish National Cancer Research Centre
  • Developer AUM Biosciences; Inflection Biosciences; Royal College of Surgeons
  • Class 2 ring heterocyclic compounds; Antineoplastics; Aza compounds; Ethers; Fluorobenzenes; Ketones; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Lung cancer; Neuroblastoma; Prostate cancer

Most Recent Events

  • 09 Jun 2023 Chemical structure information added
  • 06 May 2023 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the Digestive Disease Week 2023 (DDW-2023)
  • 05 Jan 2023 AUM 302 receives Rare Paediatric Disease designation from the US FDA for treatment of Neuroblastoma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top